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Hypoxic Ischemic Encephalopathy (HIE)
Necrotizing Enterocolitis (NE)
• Human asphyxia neonatorum
• No effective resuscitation
• No ventilator support
• 70% good response
Hutchinson JH, et al. Lancet 1963;ii:1019:1022
History HIE
• Respiratory insufficiency
• Hypoxic ischemic 
encephalopathy
• Severe infections / Sepsis
• Traumatic brain injury 
• Cardiologic
Estrin VV, et al. Proc 7th Int Cong Hyper Med 1981:343
Bayboradov BD. Proc 7th Int Cong Hyper Med 1981:299-312
Pilinoga VG, et al. Proc 7th Int Cong Hyper Med 1981:292-294
USSR - 1413
History HBO in Neonates
Carotid Ligature
8% oxygen - 2 hours
HBO 3 atm abs / 60 min





Calvert J, et al. Brain Research 2002,951:1-8
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Abstract
Objectives: Describe the use of HBO2 in the management of acute ischemic hypoxic encephalopathy.
Materials and Methods: The therapeutic mechanisms of hyperbaric oxygen in acute ischemic hypoxic encephalopathy are outlined,
based on information obtained from peer-reviewed medical literature.
Results: HBO2 promotes survival of marginal tissue (penumbra), reduces edema, improves microcirculation, breaks the edema-
hypoxia-edema vicious cycle, enhances healing, promotes growth factors up-regulation and improves neovascularization. At cellular
level, it maintains the levels of ATP, restores mitochondrial dysfunction, reduces oxidative stress and apoptosis, and promotes anti-
oxidant effects. HBO2 did not show significant differences in fatality rates at six months (RR0.97, 95%CI 0.34 to 2.75, p=0.96). It
showed improvement in the disability and functional performance scales. Trouillas Disability Scale was lower with HBO2 (MD 2.2
point reduction with 95%CI 0.15 to 4.3, p=0.04), and the mean Orgogozo Scale was higher (MD 27.9 points, 95%CI 4.0 to 51.8,
p=0.02).
Conclusion: When used promptly, HBO2 can modify cerebral inflammation, ischemia, hypoxia, and ischemia-reperfusion injury. It
helps preserve marginal tissue and recover the ischemic and metabolic penumbra. A prospective, randomized, and controlled study
within the window of opportunity (< 5h) in a stroke center is needed, to determine the real use of HBO2 in these cases.
Keywords: Acute ischemic hypoxic encephalopathy, Hyperbaric oxygenation, Ischemia-reperfusion-injury, Mitochondrial dysfunction
Introduction
Acute ischemic-hypoxic encephalopathy (stroke) is the most important preventable cause of disability for Americans and the second
cause of death worldwide. Every year, more than 795,000 people in the US have a stroke and about 610,000 of these, are first or new
strokes. About 25% of strokes (185,000) happen in people who had a previous stroke. The prevalence of stroke (2009-2012) for people
aged 20-39, was 0.2 for men and 0.7 for women; for ages 40-59, 1.9 for men and 2.2 for women; for ages 60-79, 6.1 for men and 5.2
for women; and for ages 80+, 15.8 for men and 14.0 for women. About 87% of all strokes are ischemic strokes [1-3].
The risk of having a stroke varies with race and ethnicity. The risk of having a first stroke is nearly twice as high for African Americans
compared to whites, and African Americans are more likely to die following a stroke than are whites. Hispanics’ risk of stroke falls
between that of whites and African Americans. American Indians, Alaska Natives, and African Americans are more likely to have had
• 20 of 1,000 full term deliveries 
- 25% neonatal death (8% @ 5 years)
- CP 2/1,000
• 60% premature live births
• Leading cause of infant fatalities (USA)
• Hospital stay – 4.8 days (10.9)
• C t 34 billio  USD / year
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• Pregnancy > 34.5 sem
• Weight  > 1.2 kg
• Resucitation > 8 min
• Apgar < 3 y < 5
• pH < 7.2








• Follow-up 4 h post 
HBO 
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Pub, 2008:427-442
Sánchez EC. Austin J Cerebrovasc Dis Stroke 2016;3(2):1046
Protocol HBO in Neonates
• 1.8 - 2.0 atm abs 
• 45 minutes
- 20 min - oxygen
- 5 min - air
- 20 min - oxygen
• qd or bid
• 1 - 4 treatments
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Pub, 2008:427-442
Sánchez EC. Austin J Cerebrovasc Dis Stroke 2016;3(2):1046
Protocol HBO in Neonates
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Publishing, 2008:427-442
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
HBO in Neonates
• Promotes viability of CNS
• Reduces edema (Doppler TF)
• Normalizes EEG
• Normalization EP 
• Improves laboratories studies
• Funduscopic studies
• Follow – up 1 / 3 / 6 / 12 month 3 / 5  years
- Small attention deficit – 1 case
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Pub, 2008:427-442
Sánchez EC. Austin J Cerebrovasc Dis Stroke 2016;3(2):1046
HBO in Neonates
• N = 60
• 1.4 – 1.6 ATA / 60 min QD / 7 days
• > SOD
• < NOS / NO
• P < 0.01
• No changes in funduscopic study
Zhou BY, et al. Ahongguo Dang Dai Er Ke Za Zhi 2008;10(2):133-135
HBO in Neonates - Mortalidad
Liu Z, et al. BMJ 2006;333(7564):374
HBO in Neonates – Neuro Sequelae
Liu Z, et al. BMJ 2006;333(7564):374
• Pathophysiology







Hsueh W, et al. Acta Pediatr Suppl 1994;396:11-17
Downard CD, et al. J Pediatr Surg 2011;46(6):1023-1028
Frost BL, et al. Semin Pediatr Surg 2013;22(2):88-93



















Antagonist PAF      
- +
Downard CD, et al. J Pediatr Surg 2011;46(6):1023-1028
Thornton NL, et al. Neonatology 2012;10(2):140-146
Garzoni L, et al. Frontiers Integrat Neurosci 2013;7(57):1-9
Rentea RM, et al. Eur J Pediatr Surg 2013;23(1):39-47
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289


Test Basal Control P Value 
Hemoglobin 14.1+-1.47 16.2+-.29 0.02 
Hematocrit 42.48+-4 47.86+-2 0.05 
Proteín Total  4.94+-.92 5.6+-41 0.05 
Sodium 133.2+-8.31 141.2+-3.56 0.04 
Triglicerides 108+-60 88.4+-47 0.03 
Bilirrubina Dir 2.33+-3.6 3.02+-4.04 0.04 
pH 7.3+-9.35 7.39+-.03 0.05 
 
 
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Publishing, 2008:427-442
Test Basal Control P Value 
Neutr seg 62.6+-17.42 60.8+-14.68 0.81 
Basofils 0.2+-.4 0.4+-.9 0.70 
TP                    37.78+-22.85 27.62+-17.8 0.19 
TPT 69.7+-26.48 48.3+-15.9 0.22 
TT 85+-48.6 67.2+-45.38 0.08 
Fibrinogen 370+-108 317+-107 0.13 
Creatinine                     2.36+-1.83 1.64+-1.25 0.20 
 
 
Sánchez EC. Crit Care Nurs Q 2013;36(3):280-289
Sánchez EC, et al. Hyperbaric Oxygen for Neurological Disorders. Best Publishing, 2008:427-442







- 45% long periods
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Carga Global de Enfermedad
Global Burden of Disease - DALY
Patients YLL YLD DALY
9 669.6 200.88 870.481
Pacientes YLL YLD DALY
9 669.6 200.9 870.5
• 11 RCT
• n = 1505
• Reduction of mortality / major 
neurodevelopmental disability – 18 months




Jacobs SE, et al. Cochrane Database Sys Rev 2013. CD003311.
Hypothermia for HIE
“Acute neonatal hypoxia is so common 
and devastating that a small difference in 
salvaged tissue may make a big difference 
in quality of life.”
“Anyone who doesn´t believe 
in miracles... Is not a realist” 
Gracias
